NFKB1 and neoplasm: Given the interplay between EMT and inflammation in cancer, where pro-inflammatory cytokines like TGF-β and NF-κB drive EMT (68), CD109’s capacity to modulate these processes and cancer progression suggests that CD109 promotes SCC tumor progression through these pathways.